AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

AbCellera Biologics Inc.NASDAQ: ABCL

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) growth accelerates

Q3 FY2026 weighted avg shares (diluted) of 318.05M shares rose 6.4% year over year, ahead of the +3.0% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 4.1% from the prior quarter. Over 3 fiscal years it compounded at -1.7% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +6.4% holds above the trailing-twelve-month pace of +3.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
318.05M+4.1% QoQ
Last fiscal yearDec 2025
298.71M+1.5% YoY
LTMSep 2026
306.35M+3.0% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.4%——
1 year+1.5%——
3-year CAGR-1.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
298.71M USD
Year-over-year change
+1.5%
4-year CAGR
-1.6%

Weighted Avg Shares (Diluted) vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 weighted avg shares (diluted) of 306.35M shares is the highest of the 4 companies compared; the peer median is 56.38M shares.
  • Its year-over-year change of +3.0% is the 3rd highest of 4, against a peer median of +7.5%.
  • Over three fiscal years its annual growth of -1.7% compares with a peer median of +12.2%.
ABCL Competitors Peer median
Weighted Avg Shares (Diluted) for ABCL and competitors
Company Period LTM YoY 3-year CAGR
ABCLAbCellera Biologics Inc.LTM Sep 2026306.35M +3.0%-1.7%
ABSIAbsci CorporationLTM Mar 2026143.73M +23.4%+14.6%
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 202656.38M +7.5%+9.7%
GENBGenerate Biomedicines, Inc.FY202550.09M -60.7%—
Peer median (excluding ABCL) 56.38M+7.5%+12.2%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue375.2M485.42M38.03M28.83M75.13M
Cost of Revenue45.52M66.44M0028.82M
Gross Profit329.69M418.99M38.03M28.83M46.31M
Gross Margin87.9%86.3%100.0%100.0%61.6%
Research & Development62.06M107.88M175.66M167.26M186.83M
Selling, General & Admin48.76M66.76M75.18M85.49M76.58M
Operating Expenses125.27M202.48M275.23M343.6M263.41M
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
EBITDA239.15M260.17M(192.16M)(204.15M)(148.77M)
EBITDA Margin63.7%53.6%-505.3%-708.0%-198.0%
Operating Income204.41M216.51M(237.21M)(314.77M)(217.1M)
Operating Margin54.5%44.6%-623.8%-1091.7%-289.0%
Interest Income3.33M16.08M42.25M38.47M28.33M
Interest Expense5.23M4.05M000
Other Income / Expenses14.74M22.59M63.18M114.37M39.51M
Income Before Tax219.15M239.1M(174.03M)(200.4M)(177.6M)
Pre-Tax Margin58.4%49.3%-457.7%-695.0%-236.4%
Income Tax Expense65.69M80.58M(27.63M)(37.54M)(31.18M)
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Net Margin40.9%32.7%-385.0%-564.8%-194.9%
EPS (Basic)0.560.56(0.51)(0.55)(0.49)
EPS (Diluted)0.480.50(0.51)(0.55)(0.49)
Weighted Avg Shares275.76M285.06M289.17M294.33M298.71M
Weighted Avg Shares (Diluted)318.29M314.83M289.17M294.33M298.71M

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.